More importantly, our preliminary data also found that this “double-edged” aspect was not only observed in OSCC, but also in a variety of CYLD-negative malignant cancers, such as triple negative breast cancer, ovarian cancer, and NSCLC (data not shown). This evidence concerns the gene CYLD and ovarian cancer.